Related Experiment Video
Updated: Sep 3, 2025
In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
Published on: March 7, 2025
Fatty Acids: A Safe Tool for Improving Neurodevelopmental Alterations in Down Syndrome?
Carmen Martínez-Cué1, Renata Bartesaghi2
1Departamento de Fisiología y Farmacología, Facultad de Medicina, Universidad de Cantabria, 39011 Santander, Spain.
Insights
Fatty acids show promise for treating neurodevelopmental and cognitive deficits in Down syndrome (DS). Research in DS mouse models suggests these dietary nutrients could offer a safe and effective therapeutic strategy.
Area of Science:
- Neuroscience
- Genetics
- Metabolic Disorders
Background:
- Down syndrome (DS), caused by trisomy 21, is characterized by intellectual disability (ID) stemming from prenatal and postnatal neurodevelopmental impairments.
- These neurodevelopmental issues in DS are linked to altered mitochondrial function, metabolism, and accelerated aging, increasing Alzheimer's disease risk.
- Current pharmacotherapy research for DS relies on mouse models, but potential human safety concerns exist for early-life treatments.
Purpose of the Study:
- To review the impact of fatty acids on brain function, particularly in the context of Down syndrome.
- To evaluate recent findings from a DS mouse model investigating fatty acid interventions.
- To explore the potential of fatty acids as a therapeutic approach for Down syndrome.
Main Methods:
- Review of existing animal model data on fatty acid effects in the brain, focusing on DS-relevant alterations.
- Analysis of recent progress in a Down syndrome mouse model examining fatty acid treatments.
- Synthesis of evidence to support the potential therapeutic role of fatty acids in DS.
Main Results:
- Animal models demonstrate beneficial effects of fatty acids on brain development and function.
- Recent studies in a DS mouse model indicate that fatty acids can ameliorate neurodevelopmental deficits.
- Fatty acids present a promising avenue for therapeutic intervention in Down syndrome.
Conclusions:
- Fatty acids, essential dietary nutrients, exhibit neuroprotective and neurodevelopmental benefits.
- Evidence from DS mouse models suggests fatty acids may be a viable treatment strategy for neurodevelopmental and cognitive impairments.
- Further research into fatty acid supplementation for individuals with Down syndrome is warranted.
Abstract:
The triplication of chromosome 21 causes Down syndrome (DS), a genetic disorder that is characterized by intellectual disability (ID). The causes of ID start in utero, leading to impairments in neurogenesis, and continue into infancy, leading to impairments in dendritogenesis, spinogenesis, and connectivity. These defects are associated with alterations in mitochondrial and metabolic functions and precocious aging, leading to the early development of Alzheimer's disease. Intense efforts are currently underway, taking advantage of DS mouse models to discover pharmacotherapies for the neurodevelopmental and cognitive deficits of DS. Many treatments that proved effective in mouse models may raise safety concerns over human use, especially at early life stages. Accumulating evidence shows that fatty acids, which are nutrients present in normal diets, exert numerous positive effects on the brain. Here, we review (i) the knowledge obtained from animal models regarding the effects of fatty acids on the brain, by focusing on alterations that are particularly prominent in DS, and (ii) the progress recently made in a DS mouse model, suggesting that fatty acids may indeed represent a useful treatment for DS. This scenario should prompt the scientific community to further explore the potential benefit of fatty acids for people with DS.
